In the lead up to its capital markets day, Basilea Pharmaceutica announced it has received initial funding of up to US$0.9m through a...

SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and...

Basilea Pharmaceutica has announced the FDA approval of its second lead asset, Zevtera (ceftobiprole), for the treatment of severe...

SIGA Technologies has delivered its best top-line performance in the last five years, supported by a late surge in TPOXX deliveries...

FY23 was another strong year for Basilea Pharmaceutica, marked by successive guidance beats and meaningful progress in fortifying its...

Basilea Pharmaceutica has announced a preclinical antibiotic programme asset purchase agreement, aligning with management’s pre-emptive...

Basilea Pharmaceutica has announced an exclusive evaluation licence and option agreement with South Korea-based iNtRON Biotechnology...

Basilea Pharmaceutica has announced that the US FDA has accepted its New Drug Application (NDA) for ceftobiprole. The FDA has set a...

Personalised treatment continues to be a major theme observed at the annual American Society of Clinical Oncology (ASCO) meeting, much...

Basilea Pharmaceutica has announced receipt of two separate sales-related milestone payments totalling US$26.25m (CHF23.7m) from...

Basilea Pharmaceutica has announced that there will be a minor delay in the timing of its new drug application (NDA) for Zevtera...

ERGOMED, a services business which includes an industry-leading suite of specialist pharmacovigilance solutions, reported FY22 results...